FDA To Give Priority Review to Melanoma Drug

The Wall Street Journal

Bristol-Myers Squibb Co. said Wednesday the Food and Drug Administration agreed to give a priority review to its experimental advanced melanoma treatment, ipilimumab.

The review will focus on the use of the drug ... Read More (access limited)